| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/28/2005 | US20050090493 Useful as anti-cancer agents; exhibit apoptotic effect in a warm-blooded animal such as man; for example, 2-{4-[3-(N,N-Dimethyl)amino-2-hydroxy-propoxy]anilino}-4-(2,4-difluoro-(N-cyanomethyl)anilino)pyrimidine |
| 04/28/2005 | US20050090491 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/28/2005 | US20050090490 3-Substituted-4-pyrimidone derivatives |
| 04/28/2005 | US20050090489 An alpha hydroxy acid or a retinoid as a bacterial fermentation product of a novel Streptomyces strain; topical antiwrinkle agents |
| 04/28/2005 | US20050090488 Drug combination for the treatment of depression and related disorders comprising mirtazapine |
| 04/28/2005 | US20050090487 Cardiovascular disorders; antiinflammatory agents |
| 04/28/2005 | US20050090486 Trisubstituted pyrimidines |
| 04/28/2005 | US20050090485 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| 04/28/2005 | US20050090483 Purine derivatives as kinase inhibitors |
| 04/28/2005 | US20050090482 Potentiators of antibacterial activity |
| 04/28/2005 | US20050090481 having improved stability and side effect reduction; tissue-targeted therapy |
| 04/28/2005 | US20050090480 preventing malaria comprising administering drugs that inhibition of growth of the malarial parasite, plasmodium falciparum, along with phosphono derivatives and/or other drugs; parasiticides |
| 04/28/2005 | US20050090479 transition metal complexes that can mediate direct and specific strand scission targeted to a single base with a significantly high level of recognition such that cleavage occurs at a limited number of sites along a target polynucleotide; antitumor agents |
| 04/28/2005 | US20050090478 Platinum complexes and their use in cancer treatment |
| 04/28/2005 | US20050090475 administering a combination of estrogen and a progestin for 42 consecutive days followed by a hormone-free period of from 4 to 8 days, where the estrogen dosage remains constant over each 21 day cycle and the progestin dosage increases in three phases over each day cycle |
| 04/28/2005 | US20050090474 Methods and compositions for enhancing and inhibiting fertilization |
| 04/28/2005 | US20050090473 Formulations and methods of treating inflammatory bowel disease |
| 04/28/2005 | US20050090471 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 04/28/2005 | US20050090470 alkylation of 1,3-diaminopropane or addition to diethyl vinylphosphonate, to form N-(3-aminopropyl)aminoethanephosphonic acid diethyl ester, which is condensed with a squarate compound to give drugs used as N-methyl-D-aspartic acid (NMDA) antagonists |
| 04/28/2005 | US20050090469 Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
| 04/28/2005 | US20050090467 administering 4-thiouridine, isomaltitol and uridine as antiinflammatory agents and/or problems in hemostasis related to platelet function |
| 04/28/2005 | US20050090463 7-(2'-C-methyl- beta -D-ribofuranosyl)-4-amino-5-(2'-trimethylsilylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine; treating hepatitis C; viricide mixture contains other active drugs |
| 04/28/2005 | US20050090461 Synthesizing polyketide fusion protein comprising acyltransferase domain for use as anthelminthic, insecticide, antitumor, immunosuppressant, fungicidal and/or bactericidal agents |
| 04/28/2005 | US20050090460 9a,11-3C-bicyclic 9a-azalide derivatives |
| 04/28/2005 | US20050090459 Crystal forms of azithromycin |
| 04/28/2005 | US20050090457 Method of treating mammals with genistein and/or genistein analogues |
| 04/28/2005 | US20050090455 for prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. |
| 04/28/2005 | US20050090454 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
| 04/28/2005 | US20050090453 controlling B-cell differentiation factors using alkaloids; drug screening; bone disorders; immunology |
| 04/28/2005 | US20050090452 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| 04/28/2005 | US20050090451 Treatment of cancer with glutamine |
| 04/28/2005 | US20050090450 enzyme inhibitors such as Pyrazine-2-carboxylic acid (cyclohexyl-{1-[2-(1-cyclopropylaminooxalyl-butylcarbamoyl)-3-isopropyl-pyrrolidine-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-methyl)-amide, used for treating viral diseases or pretreatment of medical equipment |
| 04/28/2005 | US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models: |
| 04/28/2005 | US20050090440 Tumour treating combinations, compositions and methods |
| 04/28/2005 | US20050090433 Dalbavancin compositions for treatment of bacterial infections |
| 04/28/2005 | US20050090431 Water soluble prodrugs of hindered alcohols |
| 04/28/2005 | US20050090428 Porphyrins with virucidal activity |
| 04/28/2005 | US20050090427 Delivery of drugs to the bloodstream in toothpaste |
| 04/28/2005 | US20050090426 in mammals by administering drugs which inhibits the expression or activity of microsomal triglyceride transfer proteins; antiinflammatory agents; enzyme inhibitors |
| 04/28/2005 | US20050089975 Culturing a methionine-producing microorganism in a fermentation medium to yield a fermentation broth; solubilizing methionine by raising temperature of the broth, removing insoluble material from fermentation broth to yield a methionine preparation, adding acid and base into the broth |
| 04/28/2005 | US20050089945 Abeta 42 lowering agents |
| 04/28/2005 | US20050089936 Such as 5-chloro-3-phenyl-1H-indole-2-carboxylic acid benzylamide; immobilization; drug screening |
| 04/28/2005 | US20050089935 Combinatorial library of 3-aryl-1h-indole-2-carboxylic acid |
| 04/28/2005 | US20050089933 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089892 Biiodrugs for diagnosis, drug screening, clinical trial monitoring, treatment of physiological disorders; viral disease and infection prevention; expression vectors |
| 04/28/2005 | US20050089887 Novel human ion channel proteins |
| 04/28/2005 | US20050089884 Genes coding for ketosynthase, acyl transferase, acyl carrier protein, ketoreductase, dehydratase and enoyl reductase domains, and genes coding for modifier enzymes, such as ABC transporter, cytochrome P450 monooxygenase, ferredoxin, thioesterase, 4-amino-4-deoxychorismate (ADC) synthase or lyase |
| 04/28/2005 | US20050089868 Modulators of tissue regeneration |
| 04/28/2005 | US20050089865 Delta 6 desaturases from primulaceae, expressing plants and pufa-containing oils |
| 04/28/2005 | US20050089592 Nut skin products |
| 04/28/2005 | US20050089591 Methods and compositions comprising Ilex |
| 04/28/2005 | US20050089586 Extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug |
| 04/28/2005 | US20050089585 Reducing levels of monocytes by administering a pharmaceutically effective amount of betel leaf extract, lyophilized betel leaf extract or a formulation comprising betel leaf extract to an animal, including a human being that is suffering from Myeloid leukemia |
| 04/28/2005 | US20050089584 Nut extract having different alkaloid profile; reduced level of carcinogens; supercritical CO2 extraction; maintaining nutraceutical effects; rapidly dissolving tablets |
| 04/28/2005 | US20050089578 Methods and devices for tissue repair |
| 04/28/2005 | US20050089577 In which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness |
| 04/28/2005 | US20050089575 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 04/28/2005 | US20050089574 Overcoating drug; sustained release; cardiovascular disorders; mixture of acrylic polymer and vinyl acetate polymer |
| 04/28/2005 | US20050089573 Oral pharmaceutical formulation containing ibandronate |
| 04/28/2005 | US20050089572 For oral administration in humans, stability in the acidic environment of the stomach |
| 04/28/2005 | US20050089571 Pharmaceutical formulation for the active ingredient budesonide |
| 04/28/2005 | US20050089570 Sustained release dosage form of a sustained release component and an immediate release component which is not an immediate release drug coating; burst release; able to deliver high doses of poorly soluble drugs (e.g. ibuprofen) at a controlled rate |
| 04/28/2005 | US20050089568 Melt-extruded orally administrable opioid formulations |
| 04/28/2005 | US20050089565 Methylcellulose and, as separate ingredients, a disintegrating agent, a binder, and a diluent; laxative for treating constipation |
| 04/28/2005 | US20050089564 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089563 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089562 First phase of a compacted mixture of methylcellulose with a viscosity greater than 1000 centipoise and an edible calcium salt, blended with a second phase that may contain a disintegrating agent, a wetting agent, a lubricant and/or a second diluent |
| 04/28/2005 | US20050089561 Blending granulated methylcellulose and granulated diluent to form an intragranulated tablet; use treating constipation |
| 04/28/2005 | US20050089560 With a diluent and a crosprovidone; treating constipation |
| 04/28/2005 | US20050089559 Flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone; pains which are accompanied by an increase in muscle tone such as neuralgia |
| 04/28/2005 | US20050089558 Treating pain; synergistic |
| 04/28/2005 | US20050089556 Composition for treating hemorrhoids |
| 04/28/2005 | US20050089555 Administering phospholipid, bile acid and water; treating adipose tissue disorders such as cellulite, tumors e.g. lipomas |
| 04/28/2005 | US20050089546 Compositions and methods comprising complex carbohydrate and alpha-lactalbumin |
| 04/28/2005 | US20050089545 Drug delivery system for the subconjunctival administration of fine grains |
| 04/28/2005 | US20050089539 Antimicrobial compositions and methods |
| 04/28/2005 | US20050089519 Bispecific anti-cd19x anti-cd16 antibodies and uses thereof |
| 04/28/2005 | US20050089518 Prospective identification and characterization of breast cancer stem cells |
| 04/28/2005 | US20050089516 Artificial skin; mixture of protein and serine protease inhibitor |
| 04/28/2005 | US20050089511 Methods and compositions comprising DNA damaging agents and p53 |
| 04/28/2005 | US20050089509 Treatment of Francisella infection with an IFN-gamma inducer and a chemotherapeutic agent |
| 04/28/2005 | US20050089506 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| 04/28/2005 | US20050089501 Composition based on natural substances useful in the maintenance of the correct hydration of the skin |
| 04/28/2005 | US20050089495 Transdermal transport of compounds |
| 04/28/2005 | US20050089487 Protective coatings for skin, hair, for use as ultravilotet radiation filters in cosmetic or pharmaceutical preparations for protecting human skin or human hair against solar rays |
| 04/28/2005 | US20050089485 Sulfacetamide formulations for treatment of rosacea |
| 04/28/2005 | US20050089479 Delivery of sedative-hypnotics through an inhalation route |
| 04/28/2005 | US20050089478 Formeratol and budesonide for treatment of respiratory system disorders such as chronc obstructive pulmonary disease |
| 04/28/2005 | US20050089477 Medicaments |
| 04/28/2005 | US20050089473 By administering one or more activators of an ATP-sensitive potassium channel in combination with one or more activators of a calcium-activated potassium channel to increase permeability of the drugs through the capillaries in the abnormal brain tissue |
| 04/28/2005 | US20050087452 Measurement degradation of fluorescent compounds; using mixture of flavonoids and vitamin e |
| 04/28/2005 | CA2549733A1 Fused-aryl and heteroaryl derivatives and methods of their use |
| 04/28/2005 | CA2549579A1 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
| 04/28/2005 | CA2543148A1 Mucous membrane bulging humor composition comprising chitosan derivative containing saccharide chain for use in condoscopic surgery |
| 04/28/2005 | CA2542925A1 Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/28/2005 | CA2542821A1 Crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride |
| 04/28/2005 | CA2542807A1 Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
| 04/28/2005 | CA2542795A1 Systems and methods for assessing neuronal degeneration |
| 04/28/2005 | CA2542765A1 Method of inhibiting secretase activity |